Literature DB >> 29315493

Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia.

Gianluigi Reda1, Ramona Cassin1, Andrea Artoni2, Bruno Fattizzo1,3, Anna Lecchi2, Silvia La Marca2, Paolo Bucciarelli2, Giorgia V Levati1,3, Flora Peyvandi2,3, Agostino Cortelezzi1,3.   

Abstract

Entities:  

Keywords:  aggregation test; bleeding; chronic lymphocytic leukaemia; idelalisib; platelets

Mesh:

Substances:

Year:  2018        PMID: 29315493     DOI: 10.1111/bjh.15052

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  1 in total

1.  The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential.

Authors:  María N Barrachina; Irene Izquierdo; Lidia Hermida-Nogueira; Luis A Morán; Amparo Pérez; Ana B Arroyo; Nuria García-Barberá; Rocío González-Conejero; Sara Troitiño; Johannes A Eble; José Rivera; Constantino Martínez; María I Loza; Eduardo Domínguez; Ángel García
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.